Neuromyelitis Optica Spectrum Disorder: Reducing Relapse

555 Canal Street,New Orleans LA 70130

13 November, 2021

Description

This program is intended for AAO attendees only. Hybrid CME Breakfast SymposiumActivity ChairPrem S. Subramanian, MD, PhD Professor of Ophthalmology, Neurology, and Neurosurgery University of Colorado School of Medicine Vice Chair for Academic Affairs Division Head, Neuro-Ophthalmology University of Colorado Sue Anschutz-Rodgers Eye Center Aurora, CO FacultyMichael S. Lee, MD Professor, Departments of Ophthalmology and Visual Neurosciences, Neurosurgery, and Neurology Mackall-Scheie Research Chair Director, Ophthalmology Residency Program Director, Neuro-Ophthalmology Service University of Minnesota Minneapolis, MN Brian G. Weinshenker, MD, FRCP(C), FAAN Professor of Neurology Alix School of Medicine, Mayo Clinic Rochester, MN OverviewNeuromyelitis optica spectrum disorder (NMOSD) is a rare, relapsing, autoimmune disease that is characterized by inflammation in the optic nerve and spinal cord. Diagnosing NMOSD is challenging, but diagnostic criteria—based on the presence of core clinical characteristics, aquaporin-4 antibody status, and magnetic resonance imaging—have been developed that allows for a differential diagnosis from other inflammatory disorders of the central nervous system. Treatment options for NMOSD have been historically limited, until recently—when the US Food and Drug Administration approved several novel therapies for the treatment and prevention of NMOSD attacks. Further therapies are currently under clinical review for the same indication. These approved and emerging therapies are changing the treatment paradigm for NMOSD, providing enhanced clinical outcomes for these patients with the goal of reducing relapse through early intervention. Within this case-based program, experts in the field will utilize didactic presentations and a panel discussion to summarize evidence-based diagnostic criteria and best practices that assist in the differential diagnosis of NMOSD, as well as differentiate current NMOSD therapeutics based on their mechanisms of action, efficacy, safety, and administration. Agenda6:00 AM Registration and Breakfast 6:30 AM Introduction and Pretest Prem S. Subramanian, MD, PhD 6:35 AM NMOSD: Diagnose Early Through Assays and Imaging Michael S. Lee, MD 6:55 AM Case Discussion: Diagnosing NMOSD Prem S. Subramanian, MD, PhD 7:00 AM NMOSD Treatments: How Do They Compare? Brian G. Weinshenker, MD, FRCP(C), FAAN 7:20 AM Case Discussion: Treating NMOSD Prem S. Subramanian, MD, PhD 7:25 AM Panel Discussion Moderated by Prem S. Subramanian, MD, PhD 7:45 AM Posttest and Question & Answer 8:00 AM Conclusion Learning ObjectivesUpon successful completion of this activity, participants should be better able to: Utilize evidence-based diagnostic criteria to improve the early detection of NMOSD. Differentiate current NMOSD therapeutics based on their mechanisms of action, efficacy, safety, and administration. Incorporate therapeutic regimens for the treatment of NMOSD based upon their safety, efficacy, as well as their ability to control acute attacks and prevent future relapses. Target AudienceThe intended audience for this activity is ophthalmologists, neuro-ophthalmologists, neurologists, optometrists and other health care professionals involved in the management of patients with NMOSD. This continuing medical education activity is provided by Vindico Medical Education. This activity is supported by an educational grant from Genentech, a member of the Roche Group. This activity is not affiliated with the official program of AAO 2021. Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Vindico Medical Education designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning and Self-Assessment requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit. In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers, and authors involved in the development of accredited content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be mitigated and disclosed to the activity audience. Faculty, topics, program schedule, and credit hours are subject to change. Recording of any manner is prohibited without written permission from the program director and the Office of Medical Affairs and Compliance. Privacy Policy Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086